Zhang Tao, Guo Jianrong, Li Huili, Wang Jiliang
Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
Oncotarget. 2017 Dec 7;9(2):2761-2769. doi: 10.18632/oncotarget.23031. eCollection 2018 Jan 5.
Phosphorylated 4E-binding protein 1 (p-4EBP1) is the inactivated form of 4EBP1, which is a downstream mediator in the mTOR signaling pathway and a vital factor in the synthesis of some oncogenic proteins. This meta-analysis was conducted to assess the predicative value of p-4EBP1 expression in human malignancies. The PubMed and Embase databases were carefully searched. Articles comparing the prognostic worthiness of different p-4EBP1 levels in human malignancies were collected for pooled analyses and methodologically appraised using the Newcastle-Ottawa Scale (NOS). A total of 39 retrospective cohorts with an overall sample size of 3,980 were selected. Patients with lower p-4EBP1 expression had better 3-year ( < 0.00001), 5-year ( < 0.00001), and 10-year ( = 0.03) overall survival and better 3-year ( < 0.0001) and 5-year ( = 0.0005) disease-free survival. Subgroup analyses confirmed the unfavorable prognosis associated with p-4EBP1 overexpression. These findings were further validated by sensitivity analyses. Harbord and Peters tests revealed no publication bias within the included studies. It thus appears higher expression of p-4EBP1 indicates a poor prognosis in human malignancies.
磷酸化4E结合蛋白1（p-4EBP1）是4EBP1的失活形式，它是mTOR信号通路中的下游介质，也是某些致癌蛋白合成中的关键因子。本荟萃分析旨在评估p-4EBP1表达在人类恶性肿瘤中的预测价值。我们仔细检索了PubMed和Embase数据库。收集比较人类恶性肿瘤中不同p-4EBP1水平预后价值的文章进行汇总分析，并使用纽卡斯尔-渥太华量表（NOS）进行方法学评估。共选择了39个回顾性队列，总样本量为3980。p-4EBP1表达较低的患者3年（<0.00001）、5年（<0.00001）和10年（=0.03）总生存率更高，3年（<0.0001）和5年（=0.0005）无病生存率更高。亚组分析证实了p-4EBP1过表达与不良预后相关。这些发现通过敏感性分析得到进一步验证。Harbord和Peters检验显示纳入研究中不存在发表偏倚。因此，p-4EBP1表达较高似乎表明人类恶性肿瘤预后较差。
